HEMOTECH BELUX

Active

Private limited companyfounded 2001active for 25 yearsBrouwerijstraat 14, 8680 Koekelare, Belgium20 active companies are registered at this addressKBO/BCE: BE 0474.412.845

Summary

HEMOTECH BELUX has been active since 2001 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €859,416 and a net result of €23,980. Equity is growing by about 27% per year across the filed financial years. Its solvency ranks better than 24% of 9,797 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.9% (low).

Risk analysisFollow Report Compare

HEMOTECH BELUXActiveChecked score 66/100

Risk analysis Report Compare

Activity

Wholesale of pharmaceutical and medical goods

NACE 46460

6th largest company by total assets in Koekelare, Wholesale and retail trade sector1 site

Size

≈ €6.3mturnover 2025, estimated

Staff: 10.6 FTE
Equity: €859,416
Profit: €23,980

Turnover estimated from the gross margin

Financial health

66 Healthy Checked score 2025

Bankruptcy probabilitywithin 12 months: 0.9%

Structure

Parent: POLLET MEDICAL GROUP · 100%

LINUSDirector · permanent representative Kris OORTS
POLLET MEDICAL GROUPDirector · permanent representative POLLET Sofie
SMARDIXDirector · permanent representative TAILLIEU Dimitri Alice Caroline

Auditor: BOES & VERRUE BEDRIJFSREVISOREN2025 accounts 22 days early6 of 11 deeds summarised

Why 66raises riskLiquidity: current ratio 1.28, cash €0, halvedEquity €859,416 (17.3% of total assets)lowers riskFounded in 2001Figures for financial year 2025 (filed 09-07-2026)Show the evidence

Checked score

Score 2025

66 / 100

Healthy

Probability in this band: 0.55% to 1.5%

Financially better than 29% of its sector peers (NACE 46, small)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Weak

Solvency 42-2

equity 17.3% of total assets

Liquidity 13-3

short-term debt 68.6% · cash 0.0%

Profitability 55+6

return on assets 0.5%

Bankruptcy probability, 12 months

0.9% Low

0%0.5%1.5%4%10%≥ 25%

About 9 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (4,374 companies, NACE 46, small)

Last 24 months 11-2024: 1.2% 12-2024: 1.2%● unchanged vs 11-2024 01-2025: 1.2%● unchanged vs 12-2024 02-2025: 1.2%● unchanged vs 01-2025 03-2025: 1.3%▲ +0.1 percentage points vs 02-2025 04-2025: 1.4%▲ +0.1 percentage points vs 03-2025 05-2025: 1.4%● unchanged vs 04-2025 06-2025: 1.4%● unchanged vs 05-2025 07-2025: 1.6%▲ +0.2 percentage points vs 06-2025highest value 08-2025: 0.7%▼ -0.9 percentage points vs 07-2025lowest value 09-2025: 0.7%● unchanged vs 08-2025lowest value 10-2025: 0.7%● unchanged vs 09-2025lowest value 11-2025: 0.7%● unchanged vs 10-2025lowest value 12-2025: 0.7%● unchanged vs 11-2025lowest value 01-2026: 0.7%● unchanged vs 12-2025lowest value 02-2026: 0.7%● unchanged vs 01-2026lowest value 03-2026: 0.7%● unchanged vs 02-2026 04-2026: 0.8%▲ +0.1 percentage points vs 03-2026 05-2026: 0.8%● unchanged vs 04-2026 06-2026: 0.8%● unchanged vs 05-2026 07-2026: 0.8%● unchanged vs 06-2026 08-2026: 0.9%▲ +0.1 percentage points vs 07-2026 09-2026: 0.9%● unchanged vs 08-2026 10-2026: 0.9%● unchanged vs 09-2026

Credit of up to €55,000 on 30-day terms is acceptable

Liquidity tight (current ratio 1.28, compared with 1.28 in 2024, below the usual 1.5; short-term debt: 68.6% and cash: 0% of total assets), and 82.7% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small): better than 19% on solvency, 11% on liquidity, 38% on profitability and 47% on growth.

The bankruptcy probability was computed on 30-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.

lowers riskraises riskneutral

Liquidity: current ratio 1.28, cash €0, halved

NBB · annual accounts

Equity €859,416 (17.3% of total assets)

NBB · annual accounts

Founded in 2001

Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.

KBO

Figures for financial year 2025 (filed 09-07-2026)

NBB · annual accounts

Weak solvency vs sector

Solvency (equity / total assets) is in the sector's weakest quartile: better than 24% of 9797 sector peers (2025).

NBB · sector comparison

Position among 9797 sector peers

Solvency

better than 24%

← weakest strongest →

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 09-07-2026, 22 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

22 days early

2024

3 days early

2023

5 days early

2022

3 days early

2021

31 days early

2020

31 days early

2019

31 days late

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 9 days before the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 27 July (5 of the last 5 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

30-10-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

09-07-2026 Annual accounts filedfinancial year 2025 · abbreviated…
12-11-2025 Appointments: BOES & VERRUE BEDRIJFSREVISOREN (statutory…Gazette deed
28-07-2025 Annual accounts filedfinancial year 2024 · abbreviated…

Key points

Caution: Result fell in 2025from €118,944 to €23,980 ▼ 79.8% View
Positive: 6th largest company by total assets in Koekelare, Wholesale and retail trade…in the Checked rankings No. 6 View
Controlled by POLLET MEDICAL GROUPultimately: POLLET GROUP 100% View
Positive: Filed on time since financial year 2020accounts within the deadline every year 6 years View

By topic

Financials

Financial year: 2025
Total assets: €5.0m
Profit: €23,980
Solvency: 17.3%

Total assets▲ 14.8%

Net result

20182025

Go to Financials

Board & ownership

Board: 3 members
Parent: POLLET MEDICAL GROUP · 100%
Auditor: BOES & VERRUE BEDRIJFSREVISOREN

LINUSDirector
POLLET MEDICAL GROUPDirector
SMARDIXDirector

Go to Board & ownership

Network & group

Group: POLLET GROUP
Connected companies: 21

Go to Network & group

Timeline

Events: 34
Since: 2003
Next accounts: by 31-07-2027

31-12-2024Back to profit
24-10-2024Resignations & appointments
26-07-2024Annual accounts filed

Go to Timeline

Company details

Sites: 1

Legal form: Private limited company
Activity: Wholesale of pharmaceutical and medical goodsNACE 46460
Founded: 26-03-2001
Year ends: 31-12
Peppol: Reachable for e-invoices

Go to Company details

Articles of association

Provisions read: 1

See the provisions in the deeds

Go to Articles of association

Key facts about HEMOTECH BELUX

What is the company number of HEMOTECH BELUX?: 0474.412.845. In Belgium the VAT number is the company number with BE in front: BE 0474.412.845.
Where is HEMOTECH BELUX based?: The registered office is at Brouwerijstraat 14, 8680 Koekelare.Company details
What does HEMOTECH BELUX do?: According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
What is the legal form of HEMOTECH BELUX?: Private limited company (BV).
When was HEMOTECH BELUX founded?: On 26-03-2001.
Is HEMOTECH BELUX still active?: Yes, HEMOTECH BELUX is an active enterprise in the KBO register.
How many employees does HEMOTECH BELUX have?: On average 10.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of HEMOTECH BELUX?: Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is HEMOTECH BELUX profitable?: In financial year 2025, HEMOTECH BELUX made a profit of €23,980.
Where can I find the annual accounts of HEMOTECH BELUX?: HEMOTECH BELUX filed 24 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of HEMOTECH BELUX due?: By 31-07-2027, for financial year 2026.Timeline